Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Commits To Patent Linkage And Extensions

Data Protection Also Included In Deal

Executive Summary

The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions. 

You may also be interested in...



India And China Criticized By US Over IP

India and China have once again come under fire from the US over intellectual property protections, in the US Trade Representative’s latest “Special 301” report.

China Provides Patent Linkage In Latest Law Draft

In a significant development, China proposes to strengthen the protection of new drugs through not only patent linkage but also patent compensation in the latest draft of its revised Patent Law.

USMCA Passes Muster In US Senate

The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.

Related Content

Topics

UsernamePublicRestriction

Register

GB149525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel